Donation

Donate
Myeloma Minute

Myeloma 101/Overview
Dr. Brian Durie

Black Swan Research Initiative Perspectives
Dr. Ola Landgren

Webcast from the 2014 Boca Raton Patient & Family Seminar 
February 28 - March 1, 2014

ASCO EHA ide-cel bb2121 initial KarMMA results myeloma 2020
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results
Read more
Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients
Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients
Read more
Previous Post
Global Advances in Myeloma: Providing Best Options for Treatment in 2015
Next Post
BOCA PNF 2014: Best Therapies for Elderly Patients/Best Therapies for Patients Opting for Transplant

Give Where Most Needed

Learn More